An FDA panel is slated to review Amgen Inc.’s (AMGN) Biologics License Application for ABP 501, a proposed biosimilar to AbbVie Inc.'s (ABBV) Humira on July 12, 2016.The BLA for ABP 501 represents Amgen's first biosimilar application to the FDA. The regulatory agency’s final decision on ABP 501 is set for September 25, 2016. The FDA usually follows the recommendations of its advisory panels, although it is not required to do so. AbbVie's Humira is approved to reduce the signs and symptoms of moderate to severe rheumatoid arthritis in adults, moderate to severe polyarticular juvenile idiopathic arthritis in children 2 years of age and older, psoriatic arthritis in adults, ankylosing spondylitis in adults, moderate to severe Crohn's disease in adults and children, moderate to severe hidradenitis suppurativa in adults, moderate to severe ulcerative colitis and moderate to severe chronic plaque psoriasis in adults.Humira raked in sales of $14 billion in 2015, and was the world’s best-selling drug of the year.